SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-20-297087
Filing Date
2020-11-18
Accepted
2020-11-18 17:16:01
Documents
12
Period of Report
2020-11-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d93148d8ka.htm   iXBRL 8-K/A 26611
  Complete submission text file 0001193125-20-297087.txt   159348

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rtrx-20201112.xsd EX-101.SCH 2728
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rtrx-20201112_lab.xml EX-101.LAB 19760
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rtrx-20201112_pre.xml EX-101.PRE 12335
5 EXTRACTED XBRL INSTANCE DOCUMENT d93148d8ka_htm.xml XML 5066
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36257 | Film No.: 201325979
SIC: 2834 Pharmaceutical Preparations